随着用于体液分子生物标志物研究的尖端技术不断发展，这些生物标志物的临床应用不断完善。多种形式的循环分子生物标志物已被描述，包括无细胞 DNA (cfDNA)、循环肿瘤细胞 (CTC) 和无细胞 microRNA (cfmiR)，尽管其适用性、特异性、敏感性和再现性仍存在未解决的问题。证明 cfmiR 在多种癌症中的临床实用性和重要性的转化研究已显着增加。本综述旨在总结过去 5 年 cfmiR 领域的转化癌症研究及其在诊断、预后和监测疾病复发或治疗反应（重点关注实体瘤）方面的潜在临床应用。 PubMed 用于文献检索，遵循基于肿瘤类型、患者样本量和临床应用的严格研究排除标准。共有 136 项关于不同实体瘤中 cfmiR 的研究被确定，并根据肿瘤类型、器官部位、发现的 cfmiR 数量、方法和分析的生物流体类型进行分类。这篇全面的综述强调了 cfmiR 的临床应用，并总结了需要更多研究和验证的服务不足领域。© 2024 作者。约翰·威利出版的《分子肿瘤学》

As cutting-edge technologies applied for the study of body fluid molecular biomarkers are continuously evolving, clinical applications of these biomarkers improve. Diverse forms of circulating molecular biomarkers have been described, including cell-free DNA (cfDNA), circulating tumor cells (CTCs), and cell-free microRNAs (cfmiRs), although unresolved issues remain in their applicability, specificity, sensitivity, and reproducibility. Translational studies demonstrating the clinical utility and importance of cfmiRs in multiple cancers have significantly increased. This review aims to summarize the last 5 years of translational cancer research in the field of cfmiRs and their potential clinical applications to diagnosis, prognosis, and monitoring disease recurrence or treatment responses with a focus on solid tumors. PubMed was utilized for the literature search, following rigorous exclusion criteria for studies based on tumor types, patient sample size, and clinical applications. A total of 136 studies on cfmiRs in different solid tumors were identified and divided based on tumor types, organ sites, number of cfmiRs found, methodology, and types of biofluids analyzed. This comprehensive review emphasizes clinical applications of cfmiRs and summarizes underserved areas where more research and validations are needed.© 2024 The Author(s). Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.